PALO ALTO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced ...
ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment can ...
Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer will ...
NEW ORLEANS -- Despite ongoing scrutiny about its safety, nexiguran ziclumeran (nex-z) still had promising effectiveness data to hold onto. In an update on nex-z's phase I study, the CRISPR-Cas9 gene ...
Cardiac transthyretin amyloidosis (also called ATTR amyloidosis cardiomyopathy or ATTR-CM) is a progressive disease and a cause of fatal heart failure resulting from extracellular myocardial ...
ATTR phenotypes vary by genotype as well as by gene penetrance, age, and geographic location. A new analysis examined data from untreated, symptomatic patients who had 1 of 4 variants: F64L, I68L, ...
When you have transthyretin amyloid cardiomyopathy (ATTR-CM), proteins called amyloids build up in your heart, stiffening the muscle and interfering with its ability to pump blood throughout the body.
Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. While cardiomyopathy is a ...
As transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, it can cause more serious problems with the heart and other parts of the body. Talking with your doctor about how the condition may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback